Grifols has introduced its direct-to-consumer programme, AlphaID At Home Genetic Health Risk Service (AlphaID At Home), in the US.
The new programme will help screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1), which is also called genetic chronic obstructive pulmonary disease.
In November 2022, the US Food and Drug Administration (FDA) approved AlphaID At Home for direct-to-consumer use.
The test can screen for the most prevalently reported genetic mutations linked to alpha-1, including the S, Z, F and I alleles, as well as rare and null alleles.
It utilises the same precise genotyping test manufactured by the company and provided to physicians worldwide since 2018 for alpha-1 screening.
Grifols Diagnostic president Antonio Martínez said: “Given the fact that it can take several years until a patient with alpha-1 is properly diagnosed, AlphaID At Home can indicate someone’s risk for alpha-1 in a matter of weeks.”
AlphaID At Home is now accessible for ordering in the US at no cost via a secure online portal that complies with HIPAA standards.
After receiving the at-home screening kit, individuals can easily collect their saliva sample and send it to a laboratory adhering to the Clinical Laboratory Improvement Amendments standards for further processing.
Individuals can access their genetic results through a secure online portal after a few weeks.
Alpha-1 Foundation president and CEO Scott Santarella said: “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1. As leaders in alpha-1 testing, Grifols is doubling down on its commitment to the alpha-1 community by making it easier and more efficient to get diagnosed.”
<!-- GPT AdSlot 3 untuk Unit Iklan 'Verdict/Verdict_In_Article' ### Ukuran: [[670,220]] -- !-- Akhiri AdSlot 3 -->- Konten Bertenaga SEO & Distribusi PR. Dapatkan Amplifikasi Hari Ini.
- PlatoAiStream. Kecerdasan Data Web3. Pengetahuan Diperkuat. Akses Di Sini.
- Mencetak Masa Depan bersama Adryenn Ashley. Akses Di Sini.
- Beli dan Jual Saham di Perusahaan PRE-IPO dengan PREIPO®. Akses Di Sini.
- Sumber: https://www.medicaldevice-network.com/news/grifols-alphaid-at-home-programme/
- :memiliki
- :adalah
- 2018
- 2022
- 220
- a
- mengakses
- dapat diakses
- Ad
- administrasi
- Setelah
- juga
- amandemen
- dan
- disetujui
- AS
- At
- by
- bernama
- CAN
- Kanker
- ceo
- Klinis
- mengumpulkan
- komitmen
- masyarakat
- perusahaan
- menyumbang
- Biaya
- kredit
- Penyakit
- dua kali lipat
- turun
- obat
- mudah
- mudah
- efisien
- akhir
- fakta
- FDA
- beberapa
- makanan
- Food and Drug Administration
- Administrasi Makanan dan Obat-obatan (FDA)
- Untuk
- Prinsip Dasar
- lebih lanjut
- mendapatkan
- Kesehatan
- membantu
- Beranda
- HTTPS
- i
- perbaikan
- in
- Termasuk
- menunjukkan
- individu
- inisiatif
- inovasi
- Lembaga
- IT
- NYA
- jpg
- kit
- laboratorium
- pemimpin
- terkait
- Membuat
- diproduksi
- hal
- lebih
- lebih efisien
- paling
- nasional
- New
- tidak
- November
- sekarang
- of
- on
- secara online
- di luar
- pasien
- plato
- Kecerdasan Data Plato
- Data Plato
- Portal
- perlu
- presiden
- pengolahan
- program
- tepat
- disediakan
- LANGKA
- menerima
- Dilaporkan
- Hasil
- Risiko
- gulungan
- s
- Tersebut
- Air liur
- sama
- Layar
- penyaringan
- aman
- mengirim
- layanan
- beberapa
- Share
- sejak
- Ukuran
- standar
- mendukung
- Mengambil
- uji
- pengujian
- bahwa
- Grafik
- mereka
- ini
- Melalui
- untuk
- satuan
- Unsplash
- sampai
- us
- menggunakan
- melalui
- minggu
- BAIK
- yang
- sepenuh hati
- akan
- dengan
- industri udang di seluruh dunia.
- tahun
- zephyrnet.dll